Macquarie

Researchers are evaluating AMT-676 in a first-in-human, open-label, multicenter Phase 1 study involving patients with advanced solid tumors. The study aims to find the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), while also assessing safety, tolerability, anti-drug activity, pharmacokinetics, pharmacodynamics, and immunogenicity of AMT-676 in this patient group. Eligible tumors include colorectal, gastric, esophageal adenocarcinoma, cholangiocarcinoma, pancreatic ductal cancers, and neuroendocrine tumors, focusing on patients who have progressed after prior therapies with no standard treatment options left.